Machuca Isabel, Gutiérrez-Gutiérrez Belén, Pérez Cortés Salvador, Gracia-Ahufinger Irene, Serrano Josefina, Madrigal María Dolores, Barcala José, Rodríguez-López Fernando, Rodríguez-Baño Jesús, Torre-Cisneros Julián
Unit of Infectious Diseases, Hospital Universitario Reina Sofía-IMIBIC-Universidad de Cordoba, Cordoba, Spain.
Unit of Infectious Diseases, Clinical Microbiology and Preventive Medicine, Hospital Universitario Virgen Macarena and Virgen del Rocío - IBiS, and Department of Medicine, Universidad de Sevilla, Sevilla, Spain.
J Antimicrob Chemother. 2016 Nov;71(11):3242-3249. doi: 10.1093/jac/dkw272. Epub 2016 Jul 26.
Invasive infections caused by KPC-producing Klebsiella pneumoniae (KPCKP) are associated with very high mortality. Because infection is usually preceded by rectal colonization, we investigated if decolonization therapy (DT) with aminoglycosides had a protective effect in selected patients.
Patients with rectal colonization by colistin-resistant KPCKP who were at high risk of developing infection (because of neutropenia, surgery, previous recurrent KPCKP infections or multiple comorbidities) were followed for 180 days. Cox regression analysis including a propensity score was used to investigate the impact of the use of two intestinal decolonization regimens with oral aminoglycosides (gentamicin and neomycin/streptomycin) on mortality, risk of KPCKP infections and microbiological success. The study was registered with ClinicalTrials.gov (NCT02604849).
The study sample comprised 77 colonized patients, of which 44 (57.1%) received DT. At 180 days of follow-up, decolonization was associated with a lower risk of mortality in multivariate analyses (HR 0.18; 95% CI 0.06-0.55) and a lower risk of KPCKP infections (HR 0.14; 95% CI 0.02-0.83) and increased microbiological success (HR 4.06; 95% CI 1.06-15.6). Specifically, gentamicin oral therapy was associated with a lower risk of crude mortality (HR 0.15; 95% CI 0.04-0.54), a lower risk of KPCKP infections (HR 0.86; 95% CI 0.008-0.94) and increased microbiological response at 180 days of follow-up (HR 5.67; 95% CI 1.33-24.1). Neomycin/streptomycin therapy was only associated with a lower risk of crude mortality (HR 0.22; 95% CI 0.06-0.9).
Intestinal decolonization with aminoglycosides is associated with a reduction in crude mortality and KPCKP infections at 180 days after initiating treatment.
产KPC肺炎克雷伯菌(KPCKP)引起的侵袭性感染与极高的死亡率相关。由于感染通常先于直肠定植发生,我们调查了氨基糖苷类药物的去定植治疗(DT)对特定患者是否具有保护作用。
对因中性粒细胞减少、手术、既往复发性KPCKP感染或多种合并症而有高感染风险的耐黏菌素KPCKP直肠定植患者进行了180天的随访。使用包括倾向评分的Cox回归分析来研究两种口服氨基糖苷类药物(庆大霉素和新霉素/链霉素)肠道去定植方案对死亡率、KPCKP感染风险和微生物学成功率的影响。该研究已在ClinicalTrials.gov注册(NCT02604849)。
研究样本包括77名定植患者,其中44名(57.1%)接受了DT。在随访180天时,多因素分析显示去定植与较低的死亡风险(HR 0.18;95%CI 0.06 - 0.55)、较低的KPCKP感染风险(HR 0.14;95%CI 0.02 - 0.83)以及更高的微生物学成功率(HR 4.06;95%CI 1.06 - 15.6)相关。具体而言,庆大霉素口服治疗与较低的粗死亡率风险(HR 0.15;95%CI 0.04 - 0.54)、较低的KPCKP感染风险(HR 0.86;95%CI 0.008 - 0.94)以及随访180天时更高的微生物学反应(HR 5.67;95%CI 1.33 - 24.1)相关。新霉素/链霉素治疗仅与较低的粗死亡率风险(HR 0.22;95%CI 0.06 - 0.9)相关。
氨基糖苷类药物进行肠道去定植与治疗开始后180天的粗死亡率降低和KPCKP感染减少相关。